Send to

Choose Destination
Curr Med Chem. 2019 Jan 23. doi: 10.2174/0929867326666190123120338. [Epub ahead of print]

Differential characteristics of HMGB2 versus HMGB1 and their perspectives in ovary and prostate cancer.

Author information

EXPRELA Group, Centro de Investigacións Científicas Avanzadas (CICA), Departamento de Bioloxía. Facultade de Ciencias, INIBIC- Universidade da Coruña, Campus de A Coruña, 15071, A Coruña. Spain.
Translational Cancer Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Carretera del Pasaje s/n, 15006 A Coruña. Spain.


We have summarized the common and differential functions of HMGB1 and HMGB2 proteins with reference to pathological processes, with a special focus on cancer. Currently, several "omic" approaches help us compare the relative expression of these 2 proteins in healthy and cancerous human specimens, as well as in a wide range of cancer-derived cell lines, or in fetal versus adult cells. Molecules that interfere with HMGB1 functions, though through different mechanisms, have been extensively tested as therapeutic agents in animal models in recent years, and their effects are summarized. The review concludes with a discussion on the perspectives of HMGB molecules as targets in prostate and ovarian cancers.


HMGB proteins; differential expression; drug targets; ovarian cancer; prostate cancer

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center